Fortress Biotech, Inc. (NASDAQ:FBIO) Shares Sold by GSA Capital Partners LLP

GSA Capital Partners LLP lessened its position in shares of Fortress Biotech, Inc. (NASDAQ:FBIO) by 58.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 81,774 shares of the biopharmaceutical company’s stock after selling 113,505 shares during the quarter. GSA Capital Partners LLP owned approximately 0.36% of Fortress Biotech worth $118,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in Fortress Biotech in the 1st quarter valued at $31,000. Atria Investments Inc increased its stake in shares of Fortress Biotech by 58.4% during the third quarter. Atria Investments Inc now owns 71,484 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 26,351 shares in the last quarter. 180 Wealth Advisors LLC acquired a new position in shares of Fortress Biotech during the 2nd quarter worth about $107,000. B. Riley Wealth Advisors Inc. acquired a new position in shares of Fortress Biotech during the 2nd quarter worth about $207,000. Finally, PVG Asset Management Corp purchased a new position in Fortress Biotech in the 2nd quarter valued at about $266,000. Hedge funds and other institutional investors own 96.51% of the company’s stock.

Insider Transactions at Fortress Biotech

In other Fortress Biotech news, CEO Lindsay A. Md Rosenwald acquired 763,359 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The shares were purchased at an average cost of $1.84 per share, for a total transaction of $1,404,580.56. Following the completion of the acquisition, the chief executive officer now owns 3,657,264 shares of the company’s stock, valued at approximately $6,729,365.76. The trade was a 26.38 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 33.40% of the company’s stock.

Fortress Biotech Stock Performance

Shares of Fortress Biotech stock opened at $1.68 on Tuesday. The business’s 50 day moving average price is $1.68 and its 200 day moving average price is $1.83. The company has a market cap of $46.37 million, a price-to-earnings ratio of -0.55 and a beta of 1.75. Fortress Biotech, Inc. has a one year low of $1.36 and a one year high of $4.43.

Analyst Ratings Changes

A number of equities analysts have commented on FBIO shares. HC Wainwright increased their target price on Fortress Biotech from $24.00 to $26.00 and gave the company a “buy” rating in a report on Monday, November 18th. StockNews.com cut shares of Fortress Biotech from a “hold” rating to a “sell” rating in a research report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $13.67.

About Fortress Biotech

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.